CAS Number82159-09-9
Synonyms(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; Epalrestat; Kinedak; (Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxothiazolidine-3-acetic acid; 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; {(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; Ono 2235
Molecular FormulaC15H13NO3S2
Molecular Weight319.40
Purity≥98 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point516.8±60.0 °C at 760 mmHg
Melting Point210-217ºC
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 82159-09-9 |
| Catalog No. | 2A-9010338 |
| Chinese Name | 依帕司他 |
| Synonyms | (Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid; Epalrestat; Kinedak; (Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxothiazolidine-3-acetic acid; 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid; {(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; {(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid; Ono 2235 |
| Molecular Formula | C15H13NO3S2 |
| Molecular Weight | 319.40 |
| Purity | ≥98 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 516.8±60.0 °C at 760 mmHg |
| Melting Point | 210-217ºC |
| Appearance | powder |
| Water Solubility | DMSO: soluble5mg/mL, clear (warmed) |
| Storage Condition | Ventilated and dried at low temperature; stored se |
| Packaging | II |
| Application | Epalrestat is an aldose reductase inhibitor that can act on diabetic neuropathy. |
| SMILES | S1\C(=C/C(=C/c2ccccc2)/C)\C(=O)N(C1=S)CC(=O)O |
| InChI | 1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8- |
| InChI Key | CHNUOJQWGUIOLD-NFZZJPOKSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | Transport |
| MSDS | msds/10338_1_82159_09_9.pdf |
| Bioactivity | Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.Target: Aldose ReductaseEpalrestat may affect or delay progression of the underlying disease process. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo. Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy [1]. Epalrestat significantly increased the amplitude of 3 cpm waves on EGG and improved the spectral analytical parameters of heart rate variability. These findings suggest that epalrestat is useful for the treatment of diabetic gastroparesis [2]. Epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy [3]. Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Aldose Reductase Research Areas >> Metabolic Disease References [1]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55. [2]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64. [3]. Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 516.8±60.0 °C at 760 mmHg Melting Point 210-217ºC Molecular Formula C15H13NO3S2 Molecular Weight 319.399 Flash Point 266.4±32.9 °C Exact Mass 319.033691 PSA 115.00000 LogP 2.02 Appearance of Characters yellow to orange Vapour Pressure 0.0±1.4 mmHg at 25°C Index of Refraction 1.706 InChIKey CHNUOJQWGUIOLD-NFZZJPOKSA-N SMILES CC(=Cc1ccccc1)C=C1SC(=S)N(CC(=O)O)C1=O Water Solubility DMSO: soluble5mg/mL, clear (warmed) |
| Use of | Properties Articles27 Name epalrestat Synonym More Synonyms Epalrestat Biological Activity Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Aldose Reductase Research Areas >> Metabolic Disease References [1]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55. [2]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64. [3]. Hotta, N., et al., Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 1996. 10(3): p. 168-72. Chemical & Physical Properties Molecular Formula C15H13NO3S2 Exact Mass 319.033691 PSA 115.00000 Appearance of Characters yellow to orange Index of Refraction 1.706 InChIKey CHNUOJQWGUIOLD-NFZZJPOKSA-N |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 United Nations shipping name European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in Nutritional Ingredients | ||
|---|---|---|
| Creatinolfosfate | 6903-79-3 | 2A-9009923 |
| Cyclocurcumin | 153127-42-5 | 2A-9009943 |
| Dialifos | 10311-84-9 | 2A-9010096 |
| Diclazuril | 101831-37-2 | 2A-9010120 |
| Dosergoside | 87178-42-5 | 2A-9010237 |
| Epanolol | 86880-51-5 | 2A-9010339 |
| Evening primrose oil | 65546-85-2 | 2A-9010433 |
| Flunitrazepan | 1622-62-4 | 2A-9010563 |
| Flurazepam | 17617-23-1 | 2A-9010578 |
| Flurazepam dihydrochloride | 1172-18-5 | 2A-9010579 |
| Browse all Nutritional Ingredients products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS